CRBP Corbus Pharmaceuticals Holdings Inc

Price (delayed)

$37.7

Market cap

$395.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.31

Enterprise value

$402.08M

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is ...

Highlights
CRBP's debt is down by 17% year-on-year and by 9% since the previous quarter
Corbus Pharmaceuticals Holdings's EPS has increased by 8% QoQ
Corbus Pharmaceuticals Holdings's net income has increased by 6% from the previous quarter but it has decreased by 5% YoY
The company's equity has shrunk by 121% YoY
The quick ratio has shrunk by 86% YoY and by 27% QoQ

Key stats

What are the main financial stats of CRBP
Market
Shares outstanding
10.49M
Market cap
$395.59M
Enterprise value
$402.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$41.68M
EBITDA
-$41.04M
Free cash flow
-$36.1M
Per share
EPS
-$10.31
Free cash flow per share
-$8.34
Book value per share
-$1.56
Revenue per share
$0
TBVPS
$6.53
Balance sheet
Total assets
$28.27M
Total liabilities
$35.18M
Debt
$20.88M
Equity
-$6.9M
Working capital
-$8.35M
Liquidity
Debt to equity
-3.02
Current ratio
0.74
Quick ratio
0.68
Net debt/EBITDA
-0.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-111.6%
Return on equity
-920.3%
Return on invested capital
-145.3%
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRBP stock price

How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-3.92%
1 week
-11.75%
1 month
7.9%
1 year
326.47%
YTD
524.17%
QTD
-3.92%

Financial performance

How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.08M
Net income
-$44.6M
Gross margin
N/A
Net margin
N/A
The operating income is down by 13% year-on-year
Corbus Pharmaceuticals Holdings's net income has increased by 6% from the previous quarter but it has decreased by 5% YoY

Growth

What is Corbus Pharmaceuticals Holdings's growth rate over time

Valuation

What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has increased by 8% QoQ
The company's equity has shrunk by 121% YoY

Efficiency

How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has shrunk by 187% QoQ
CRBP's return on invested capital has dropped by 121% year-on-year and by 41% since the previous quarter
The ROA has plunged by 109% YoY and by 16% from the previous quarter

Dividends

What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBP.

Financial health

How did Corbus Pharmaceuticals Holdings financials performed over time
Corbus Pharmaceuticals Holdings's total assets is 20% lower than its total liabilities
The quick ratio has shrunk by 86% YoY and by 27% QoQ
Corbus Pharmaceuticals Holdings's current ratio has shrunk by 84% YoY and by 25% QoQ
The company's equity has shrunk by 121% YoY
CRBP's debt to equity has dropped by 104% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.